Skip to main content
. 2015 Oct 21;20(10):19101–19129. doi: 10.3390/molecules201019101

Table 1.

Clinical Trial Information about LY573636-sodium, ABT-737, ABT-263 and ABT-199 [18].

Drug Conditions Study Start Date–Study Completion Date Phase
LY573636-sodium Brest cancer 2009‒2011 II
Sarcoma, Soft Tissue 2007‒2010 II
Ovarian Cancer 2007‒2012 II
Non-Small-Cell Lung Cancer 2006‒2008 II
Metastatic Melanoma 2006‒ongoing II
ABT-737 Breast cancer 2013‒withdrawn I/II
Ovarian cancer 2010‒2013 II
ABT-263 Chronic Lymphoid Leukemia, Lymphoid Malignancies, NoN–Hodgkin’s Lymphoma, Follicular Lymphoma, Mantle Cell, Lymphoma, Peripheral T-cell Lymphoma 2006‒ongoing II
Chronic Lymphocytic, Leukemia, Lymphomas 2008‒2010 I
Lymphoid Malignancies, Solid Tumors 2009‒2010 I
Chronic Lymphocytic Leukemia 2007‒ongoing II
Chronic Lymphocytic Leukemia 2012‒2013 II
Small Cell Lung Cancer 2007‒2010 I
Small Cell Lung Carcinoma 2007‒2010 II
ABT-199 NoN–Hodgkin’s Lymphoma 2013‒ongoing I
Chronic Lymphocytic Leukemia 2013‒ongoing I
Relapsed/Refractory Multiple Myeloma 2012‒ongoing I
Acute Myelogenous/Myeloid Leukemia 2013‒2014 II
Chronic Lymphocytic Leukemia 2014‒ongoing II
Chronic Lymphocytic Leukemia harboring the 17p Deletion, Cancer of the Blood and Bone Marrow 2013‒ongoing II